title: Flunarizine in migraine: a double-blind placebo-controlled study (in a Saudi population).
abstract: We evaluated the effect of flunarizine (Fz) (10 mg/d) on migraine in a double-blind placebo-controlled design. The attacks' frequency, duration, severity and associated symptoms were compared before and after treatment. Forty-two patients completed a three-month trial period; 21 patients received Fz and 21 placebo. Statistical analysis showed no significant difference between Fz and placebo (p > 0.05). In this study Fz was not more efficient than placebo in migraine.
authors.affiliation: Department of Clinical Neurosciences, Riyadh Armed Forces Hospital, Kingdom of Saudi Arabia.
authors.forename: S M
authors.initials: SM
authors.lastname: al Deeb
authors.forename: N
authors.initials: N
authors.lastname: Biary
authors.forename: Y
authors.initials: Y
authors.lastname: Bahou
authors.forename: M
authors.initials: M
authors.lastname: al Jaberi
authors.forename: W
authors.initials: W
authors.lastname: Khoja
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D005444:Flunarizine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D013997:Time Factors
chemical_list: D010919:Placebos; D005444:Flunarizine